Published on
06:35 GMT
Dapagliflozin Shines in Post-TAVI Patients:DAPA-TAVI Trial Findings
Dapagliflozin reduced the risk of all-cause mortality or worsening heart failure by 28% in patients with aortic stenosis undergoing transcatheter aortic valve implantation (TAVI), a new study has reported. The DapaTAVI trial, a multicenter randomized …
Source:
Medical Dialogues
-
Indeterminate
